A Milestone in Robotic Surgery
EndoQuest Robotics, Inc. has achieved a groundbreaking achievement in the field of gastrointestinal medicine by completing the first fully robotic procedure performed by a gastroenterologist as part of the PARADIGM Trial. This trial, known as the Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine, is a critical multicenter study focusing on the evaluation of EndoQuest’s Endoluminal Surgical (ELS) System. The innovative system is specifically designed for use in lower gastrointestinal tract procedures carried out by physicians, including both colorectal surgeons and gastroenterologists.
The Significance of the PARADIGM Trial
This pioneering event marks a significant first: the world’s inaugural fully robotic endoscopic submucosal dissection (ESD) performed by a gastroenterologist within an FDA Investigational Device Exemption (IDE) pivotal trial. EndoQuest recently reported that the initial cases involving the PARADIGM Trial were successfully completed at HCA Houston Healthcare and AdventHealth Orlando, with skilled colorectal surgeons Dr. Eric Haas and Dr. Matthew Albert leading the effort.
Unique Procedure by Expert Physicians
Dr. Norio Fukami, a distinguished Professor of Medicine and the Director of Therapeutic Endoscopy at Mayo Clinic, Arizona, executed a robotic ESD utilizing EndoQuest’s ELS System for the excision of a challenging colorectal lesion measuring 4 cm in diameter. Dr. Fukami’s expertise in ESD and advanced endoscopic techniques is unmatched, having previously edited the first English-language textbook on this groundbreaking surgical method.
Transformative Technology
In Dr. Fukami's words, "The device was instinctive and easy to use, allowing for dynamic traction and counter-traction of surgical technique, which simplified what is typically a very complex procedure." He emphasized that this technology represents a substantial transformation in performing ESD and various advanced endoluminal procedures. For the first time, surgeons have a reliable 'second hand' that enhances natural movements, significantly reducing the operational burden on both patients and medical professionals.
The Evolution of Endoscopic Techniques
Endoscopic submucosal dissection has gained recognition as an effective technique for managing early gastrointestinal lesions, providing patients an alternative to more invasive surgeries like colectomies. Despite its advantages, ESD poses technical challenges due to a steep learning curve related to the limitations of standard equipment. The ELS System aims to alleviate these obstacles, enabling a more straightforward execution of advanced procedures, allowing for quicker learning and improved patient outcomes.
Pre-Clinical Successes
Recent data shared by Brigham and Women’s Hospital at the Digestive Disease Week (DDW) in 2024 and 2025 revealed that the ELS System notably decreases the learning curve when compared to traditional methods for novice gastroenterologists engaging in ESD and full-thickness defect closures.
Industry Perspectives
Dr. Todd Wilson, Chief Medical Officer and Chairman of the International Advisory Board for EndoQuest Robotics, shared insights into the rapid growth of therapeutic endoscopy, noting a remarkable increase of over 50% in Advanced Endoscopy Fellowship programs in the last ten years. This trend illustrates a significant interest in pioneering endoluminal, organ-sparing treatment options, with EndoQuest poised to lead the way in this evolution.
A Commitment to Innovation
Eduardo Fonseca, CEO of EndoQuest Robotics, articulated his team's dedication to enhancing patient care through robotic technology, aiming to expand its applications not just in surgical environments but also in endoscopy suites and outpatient surgical centers. This shift promises to yield substantial clinical and economic benefits, extending far beyond ESD.
Future Goals of EndoQuest Robotics
The PARADIGM Trial is set to enroll a total of 50 participants across five of the leading healthcare institutions in the United States. Following completion, EndoQuest Robotics intends to submit a De Novo request to the FDA for the authorization to market the ELS System in the U.S. This significant step highlights their commitment to regulatory compliance and advancing robotic-assisted technologies in medicine.
Frequently Asked Questions
What is EndoQuest Robotics known for?
EndoQuest Robotics specializes in innovative endoluminal robotic surgical technologies aimed at improving patient outcomes in gastrointestinal medicine.
What is the PARADIGM Trial?
The PARADIGM Trial is a pivotal study evaluating the effectiveness of the Endoluminal Surgical System for various gastrointestinal procedures conducted by gastroenterologists and colorectal surgeons.
What is the significance of the robotic ESD procedure?
This surgery represents a major advancement in endoscopic techniques that enhances precision and ease for gastroenterologists in treating complex GI lesions.
Who is Dr. Norio Fukami?
Dr. Norio Fukami is a leading expert in therapeutic endoscopy and the Director of Therapeutic Endoscopy and Interventional Gastrointestinal Endoscopy Fellowship at Mayo Clinic.
What are the next steps for EndoQuest Robotics?
EndoQuest plans to complete the PARADIGM Trial and subsequently apply for FDA marketing authorization for their Endoluminal Surgical System.
